Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2024-02-29 | 2023-11-30 | 2023-08-31 | 2023-05-31 |
|---|---|---|---|---|
| Revenue | $16,585 | $15,159 | $18,467 | $30,676 |
| Gross Profit | 12,697 | 11,402 | 15,083 | 27,343 |
| EBITDA | -41,331 | -41,577 | -36,628 | -23,432 |
| EBIT | -45,219 | -45,334 | -40,012 | -26,765 |
| Net Income | -41,518 | -41,956 | -36,982 | -21,789 |
| Net Change In Cash | 16,585 | 15,159 | 18,467 | 30,676 |
| Free Cash Flow | -44,835 | 19,164 | -43,592 | -19,549 |
| Cash | 49,813 | 54,627 | 42,304 | 58,958 |
| Basic Shares | 54,903 | 54,670 | 54,390 | 54,259 |
Annual Financials
| Values in thousands | 2023-11-30 | 2022-11-30 | 2021-11-30 | 2020-11-30 |
|---|---|---|---|---|
| Revenue | $76,987 | $38,627 | $29,750 | $17,820 |
| Gross Profit | 63,333 | 38,627 | 29,750 | 17,820 |
| EBITDA | -141,409 | -173,059 | -111,804 | -62,803 |
| EBIT | -155,063 | -183,867 | -117,886 | -64,983 |
| Net Income | -143,948 | -166,045 | -117,194 | -43,242 |
| Net Change In Cash | 76,987 | 38,627 | 29,750 | 17,820 |
| Cost of Revenue | -15,417 | -38,734 | 84,540 | |
| Free Cash Flow | -89,766 | -172,051 | -90,026 | -4,633 |
| Cash | 54,627 | 64,474 | 80,506 | 119,356 |
| Basic Shares | 54,337 | 48,607 | 42,895 | 15,673 |
Earnings Calls
| Quarter | EPS |
|---|---|
| 2024-02-29 | -$0.76 |
| 2023-11-30 | -$0.77 |
| 2023-08-31 | -$0.68 |
| 2023-05-31 | -$0.45 |
